Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars

Posted On: 2018-01-18 04:27:17

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia's premier biopharmaceuticals company, and Sandoz, a Novartis division and a global leader in biosimilars, today announced a global partnership to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.

Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products and will have a cost and profit share arrangement globally. Worldwide commercialization responsibilities will be divided and each company's strengths will be leveraged within specific geographies. Sandoz will lead commercialization in North America* and the EU** while Biocon will lead commercialization in Rest of the World.***

Biocon Chairperson & Managing Director Kiran Mazumdar-Shaw said: "We are pleased to announce our collaboration with Sandoz for developing a set of next generation biosimilar products. This synergistic partnership will enable us to scale up our capabilities for an end to end play in the global biosimilars space. We remain committed to pursue our mission of developing biopharmaceuticals that have the potential to benefit a billion patients across the globe."

Dr. Arun Chandavarkar, CEO & Joint MD, Biocon, added: "Biocon has worked at the leading edge of science and has demonstrated its capabilities in developing high quality biosimilars. Our credibility has been further endorsed by the recent USFDA approval of our Biosimilar Trastuzumab, which is also the first in the US. Our collaboration with Sandoz will bolster our existing global biosimilars portfolio comprising biosimilar antibodies & insulin analogs and will enable us to address the next wave of global biosimilars opportunities."

As an innovation-led biopharmaceutical company, Biocon has successfully developed and taken a range of novel biologics, biosimilar antibodies, rh-insulin and insulin analogs from 'lab to market'. The collaboration with Sandoz builds upon Biocon's successful progress in its existing global biosimilars program. The most recent USFDA approval of the first biosimilar of Trastuzumab, marks an important milestone for Biocon as it is also the first biosimilar to be approved in the US for any Company from India. An early mover in the biosimilars space, Biocon has successfully launched its insulin glargine in Japan, Trastuzumab & Bevacizumab biosimilars in India and rh-Insulin, Insulin Glargine and biosimilar Trastuzumab in few emerging markets.

Sandoz is committed to increasing patient access to high-quality biosimilars and has five biosimilars currently marketed worldwide, as well as a rich global pipeline. Sandoz is well placed to strengthen its position in the biosimilars space based on its experience and capabilities in development, manufacturing and commercialization. As a division of Novartis, the first global healthcare company to establish a leading position in both innovative and off-patent medicines, Sandoz benefits strongly from this unique blend of experience and expertise in many different market environments.

Biocon's collaboration with Sandoz addresses some of the biosimilar opportunities beyond the near term opportunities being addressed by Biocon's existing successful global partnership with Mylan. This new partnership is a significant milestone in Biocon's journey of developing advanced therapies that have the potential to benefit billions of patients.

Shares of BIOCON LTD. was last trading in BSE at Rs.539.6 as compared to the previous close of Rs. 551. The total number of shares traded during the day was 163805 in over 2443 trades.

The stock hit an intraday high of Rs. 555 and intraday low of 536.75. The net turnover during the day was Rs. 88770446.

**US and Canada
**including European Free Trade Association (EFTA) and Balkan states
***including India, Russia and Commonwealth of Independent States (CIS)


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Sundaram-Clayton Ltd to consider interim dividend on Mar 15, 2018
KLRF LTD calls for Board meeting on 26/2/2018
Atlas Cycles Haryana Ltd launches India's 1st Titanium Bicycle
Vijaya Bank announces change in Composition of Board of Directors
Commercial Syn Bags Ltd to commence trial production of new unit in March 2018
CRISIL upgrades rating of Action Construction Equipment Ltd
Vesuvius India Ltd Fixes Apr 3, 2018 as Record Date for Dividend
Packaging Major Uflex to invest Rs. 1700 Crore in Uttar Pradesh
Tata Power brings Club Enerji to Ajmer, Rajasthan
HIL Ltd commences commercial production of SWR Pipes and Pressure Pipes
CMI Energy India Pvt. Ltd. bags order from Engineers India Ltd
Virat Industries Ltd announces sad demise of Mr. Naozer J. Aga
HUDCO Fixes Mar 9, 2018 as Record Date for Interim Dividend
ONGC Fixes Mar 8, 2018 as Record Date for Second Interim Dividend
Techno Electric signs agreement for investment by India Grid Trust in PTCL
Bodhtree Consulting Ltd appoints CTO
Suven Life Sciences secures Product Patents in India and South Korea
IndusInd Bank clarifies no exposure to Nirav Modi, small exposure to Gitanjali Gems
Double Negative honoured at BAFTA Awards 2018
Radhakishan Shivkishan Damani's Derive Investments buys Fortis Healthcare's shares
Indo Credit Capital Ltd calls for Board Meeting on Feb 26, 2018
Gilada Finance & Investments Ltd fixes Feb 28, 2018 as record date for dividend
Petron Engineering Construction Ltd announces resignation of 2 directors
Godawari Power and Ispat Ltd approves amalgamation of Jagdamba Power & Alloys Limited
JSW Energy enters into MoU with Maharashtra Government for Electric Vehicles plant
Chemcrux Enterprises Ltd calls for Board Meeting On February 27, 2018
ONGC Board to consider Second Interim Dividend on Feb 27, 2018
Advanced Enzyme Technologies Ltd approves additional investment in Malaysian subsidiary
Vascon Engineers Ltd signs agreement with Lina Ashar Foundation
Shilpa Medicare Ltd Board to consider Interim Dividend on Feb 22, 2018
LatestOne.com opens its largest fulfillment center in Andhra Pradesh
Housing and Urban Development Corporation Ltd to consider interim dividend on Feb 28, 2018
Airtel and HMD Global partner to offer affordable 4G smartphones
Varun Beverages Ltd arm commences production at Zimbabwe plant
Infosys Recognised as a Top Employer in Europe
Pennar Industries Limited and its subsidiaries receive orders worth Rs. 152 crores
TRENT Ltd allots Commercial Paper for Rs. 100 crores
AXIS Bank fixes 1 year MCLR at 8.40% from Feb 17, 2018
Gayatri Projects announces reorganization of energy investments in arm
Himalaya Food International Ltd opens first QSK
Shree Cement Ltd commissions new grinding unit at Aurangabad in Bihar
Quadrant Televentures Limited calls for Board Meeting On February 23, 2018
CL Educate Ltd arm sells land for Rs. 6.48 crores
Pfizer Ltd announces resignation of CFO
Goodricke Group Ltd inducts additional director
Premier Explosives receives Management System Certificate from DNV GL Business Assurance, USA
Pod Solutions and Subex partner to provide advanced security for IoT Billing and Connectivity Service
Vikas WSP Ltd receives orders for Rs. 106.23 crores
Andhra Petrochemicals Ltd announces resumption of Plant operations from 19.2.2018
Glenmark Pharmaceuticals Presents New Data on GBR 830 at the 2018 American Academy of Dermatology Annual Meeting


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018